Immunotech Biopharm Ltd
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Immunotech Biopharm Ltd - overview
Established
2006
Location
Beijing, -, China
Primary Industry
Biotechnology
About
Founded in 2006 and based in Beijing, China, Immunotech Biopharm Ltd operates as a pharmaceutical company that focuses on the development and production of cellular immunity drugs and related products. Its team members came from the Chinese Academy of Sciences, Tsinghua University, Drexel University, and other institutions and universities. Yu Wang, the founder, executive director, and chief executive officer of the company, graduated from Peking University, and has more than 20 years of experience in the field of medical research. The company cooperated with hospitals such as Peking Union Medical College Hospital and Chinese People's Liberation Army (PLA) General Hospital.
In June 2020, the company raised a pre-IPO funding for USD 40 million. In July 2020, the company was listed on the Hong Kong Stock Exchange. Immunotech Biopharm Ltd's main business is the research, development, production, and sales of cellular immunity drugs. Products include EAL, AADC, and EBV or Cytomegalovirus-specific killing T lymphocytes.
Products can be used in the fields of treating cervical lesions and improving patients' immune function. The company generates revenue by selling cellular immunity drugs. The company plans to build production centers in the Yangtze River Delta region, Pearl River Delta region, Sichuan, and Chongqing.
Current Investors
Boai Nky Medical Holdings Ltd., China Lesso Group Holdings Limited, Tasly Holding Group
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals
Website
www.eaal.net
Company Stage
Mature
Total Amount Raised
Subscriber access only
Immunotech Biopharm Ltd - financials
| Fiscal Year Ended | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 |
|---|---|---|---|---|
| Revenue (USD) | 5,218,000 | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - |
| EBITDA (USD) | (30,375,000) | - | - | - |
| Operating Income (USD) | (34,888,000) | - | - | - |
| Operating Margin | (668.6%) | - | - | - |
| % EBITDA Margin | (582.1%) | - | - | - |
| NET Income (USD) | (34,888,000) | - | - | - |
| % Net Margin | (668.6%) | - | - | - |
Immunotech Biopharm Ltd - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Chief Executive Officer | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.